FDA Awarded Aeterna Zentaris (AEZS) Special Protocol Assessment for Phase 3 Registration Trial in Endometrial Cancer with AEZS-108


Aeterna Zentaris Granted Patent by EPO for AEZS-130 in Growth Hormone Deficiency Diagnosis (AEZS, CPST)


Aeterna Zentaris and Hikma Pharmaceuticals Sign a Commercialization and Licensing Agreement for Lead Oncology Compound, Perifosine, for Middle East and North Africa (MENA) Region


(AEZS, CALL, FWLT) PennyOmega.com Watch List for Friday Nov. 25, 2011


Aeterna Zentaris Announces Favorable Top-Line Results of Completed Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency


  • Video

  • Hot stocks to watch!

    EMC Corp - EMC

    Crown Equity Holdings Inc. - CRWE.OB

    JA Solar Holdings Co Ltd - JASO

    Activision Blizzard Inc - ATVI

    iShares Down Jones U.S. Real Estate Index - IYR

    Pfizer Inc - PFE

    SanDisk Crop - SNDK

    NetApp Inc - NTAP

    Altera Corp - ALTR

    Motorola Inc - MOT

    Regions Financial Corp - RF

    Cleantech Transit, Inc. - CLNO.OB

    Huntington Bancshares Inc - HBAN

    iShares MSCI Emerging Markets Index ETF - EEM

    iShares Silver Trust ETF - SLV

    Tellabs, Inc - TLAB

    Intel Corporation - INTC

    Bucyrus International Inc - BUCY

    iShares MSCI EAFE Index ETF - EFA

    Las Vegas Sands Corp - LVS

    Alcoa Inc - AA

    Corning Inc - GLW

  •